A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 169 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 7th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
NYU Langone Health · Sites in United States
Ages 18+
Johnson & Johnson Private Limited · Sites in India
Ages 18+
University of California, San Diego · Sites in United States
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 173 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
37 studies in Arthritis, Psoriatic by Johnson & Johnson: 5 open now, 13 under way, 5 of them phase 3. Of 23 finished, 13 (57%) have results posted.
Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2021, is one of 15 in phase 3, and was the 25th registered.
Johnson & Johnson’s Arthritis, Psoriatic studies by the year they started, since 2002.
4 of the studies testing guselkumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT07141004Johnson & Johnson Private LimitedA Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | 2027-06-05 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT06586281University of California, San DiegoElucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, from their registry updates:
Among Johnson & Johnson’s 37 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
PsA is a chronic, immune-mediated inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. Guselkumab is a fully human monoclonal antibody (mAb) that binds to p19 protein subunit of interleukin (IL)-23 and blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling, subsequent activation, and cytokine production. The primary hypothesis of this study is that guselkumab is superior to placebo as assessed by the proportion of participants who had an inadequate response (IR) and/or intolerance to one prior anti-tumor necrosis factor (anti-TNF) achieving an American College of Rheumatology 20 (ACR 20) response at Week 24. This study will consist of a screening phase (up to 6 weeks), blinded treatment phase (approximately up to 2 years), which includes a placebo-controlled period from Week 0 to Week 24, and an active-controlled treatment phase from Week 24 to Week 100, and safety follow-up phase (Week 112). Safety assessments will include physical examinations, vital signs, height, weight, electrocardiograms, and clinical safety laboratory assessments. The total duration of the study will be up to 118 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
Drug: Guselkumab · Drug: Placebo
Participants will receive guselkumab SC.
Drug: Guselkumab
Participants will receive placebo SC and will cross over to receive guselkumab SC.
Drug: Guselkumab · Drug: Placebo
Participants will receive guselkumab as SC injection.
Also known as: Tremfya, CNTO1959
Participants will receive matching placebo as SC injection.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
Time frame: At Week 24
Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and greater than equal to (\>=2) grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: At Week 24
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: At Week 24
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline (pre dose Week 0) and Week 24
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline (pre dose Week 0) and Week 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline (pre dose Week 0) and Week 24
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24
MDA is a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Time frame: At Week 24
Percentage of Participants Who Achieved ACR 20 Response at Week 16
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
Time frame: At Week 16
Percentage of Participants Who Achieved ACR 50 Response at Week 16
ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
Time frame: At Week 16
Percentage of Participants Who Achieved ACR 50 Response at Week 24
ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
Time frame: At Week 24
Percentage of Participants Who Achieved ACR 70 Response at Week 24
ACR 70 response: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
Time frame: At Week 24
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From first administration of study drug (Week 0) up to Week 112
Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
Time frame: From first administration of study drug (Week 0) up to Week 112
Percentage of Participants With Treatment Emergent Related AEs (TERAEs)
Time frame: From first administration of study drug (Week 0) up to Week 112
Treatment Emergent AEs Leading to Discontinuation of Study Intervention
Time frame: From first administration of study drug (Week 0) up to Week 112
Percentage of Participants With Infections
Time frame: From first administration of study drug (Week 0) up to Week 112
Percentage of Participants With Injection-site Reactions
Time frame: From first administration of study drug (Week 0) up to Week 112
Percentage of Participants With Infusion Related Reactions
Time frame: From first administration of study drug (Week 0) up to Week 112
Number of Participants With Post-baseline Laboratory Abnormalities With Maximum Toxicity Grade Greater Than or Equal to >=3 Based on Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: From first administration of study drug (Week 0) up to Week 112
Serum Guselkumab Concentration Over Time
Serum concentrations of guselkumab over time was reported.
Time frame: At Weeks 0, 4, 8, 12, 16, 20,and 24
Number of Participants With Antibodies to Guselkumab
Number of participants with antibodies to guselkumab (ADA) were reported. A validated immunoassay was used to detect ADA.
Time frame: Baseline (pre dose Week 0) up to Week 24
| Milestone | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 150 | 152 | 151 |
| Full analysis set | 150 | 151 | 150 |
| Completed | 138 | 144 | 141 |
| Not completed | 12 | 8 | 10 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 3 | 0 |
| Withdrew: Excluded from analysis (enrolled and dosed at 2 sites) | 0 | 1 | 1 |
| Withdrew: Completed protocol-required follow-up | 1 | 2 | 2 |
| Withdrew: Discontinued study intervention and were being followed | 2 | 2 | 4 |
| Withdrew: Other | 3 | 0 | 2 |
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
| Percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | 35.9 | 63.0 | 60.9 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and greater than equal to (\>=2) grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA) | 18.8 | 60.7 | 56.8 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline | 12.5 | 47.6 | 54.9 |
The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24 | -0.2359 (-0.3200 to -0.1519) | -0.3955 (-0.4787 to -0.3122) | -0.4159 (-0.5006 to -0.3313) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24 | 3.705 (2.464 to 4.946) | 6.986 (5.758 to 8.213) | 7.027 (5.772 to 8.282) |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24 | 3.9 (2.5 to 5.3) | 7.8 (6.4 to 9.2) | 8.4 (7.0 to 9.9) |
MDA is a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24 | 5.6 | 24.8 | 20.4 |
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved ACR 20 Response at Week 16 | 30.7 | 57.5 | 53.2 |
ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved ACR 50 Response at Week 16 | 10.1 | 28.8 | 25.0 |
ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
| percantage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved ACR 50 Response at Week 24 | 12.7 | 32.9 | 33.3 |
ACR 70 response: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.
| percentage of participants | Placebo Followed by Guselkumab 100 mg | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved ACR 70 Response at Week 24 | 2.1 | 17.8 | 19.0 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Serum concentrations of guselkumab over time was reported.
| micrograms/milliliters (mcg/mL) | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Week 0 | 0.00 ± 0.003 | 0.00 ± 0.004 |
| Week 4 | 2.22 ± 1.162 | 2.32 ± 1.331 |
| Week 8 | 3.23 ± 1.789 | 3.16 ± 1.740 |
| Week 12 | 1.10 ± 0.745 | 3.45 ± 2.038 |
| Week 16 | 2.79 ± 1.436 | 3.58 ± 2.119 |
| Week 20 | 0.90 ± 0.603 | 3.61 ± 2.013 |
| Week 24 | 2.71 ± 1.347 | 3.79 ± 2.288 |
Number of participants with antibodies to guselkumab (ADA) were reported. A validated immunoassay was used to detect ADA.
| Participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Number of Participants With Antibodies to Guselkumab | 6 | 17 |
Collected over From first administration of study drug (Week 0) up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/149 (0%) | 6/149 (4%) | 18/149 (12.1%) |
| Guselkumab 100 mg q8w | 0/151 (0%) | 4/151 (2.6%) | 24/151 (15.9%) |
| Guselkumab 100 mg q4w | 1/150 (0.7%) | 2/150 (1.3%) | 16/150 (10.7%) |
| Event | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Atrial FibrillationCardiac disorders | 1/149 | 0/151 | 0/150 |
| GastritisGastrointestinal disorders | 1/149 | 0/151 | 0/150 |
| Allergy to Arthropod StingImmune system disorders | 1/149 | 0/151 | 0/150 |
| LaryngitisInfections and infestations | 1/149 | 0/151 | 0/150 |
| PyelonephritisInfections and infestations | 1/149 | 0/151 | 0/150 |
| Abnormal Uterine BleedingReproductive system and breast disorders | 1/149 | 0/151 | 0/150 |
| Myocardial InfarctionCardiac disorders | 0/149 | 0/151 | 1/150 |
| Myasthenia GravisNervous system disorders | 0/149 | 0/151 | 1/150 |
| ColitisGastrointestinal disorders | 0/149 | 1/151 | 0/150 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 0/149 | 1/151 | 0/150 |
| Event | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/149 | 9/151 | 5/150 |
| HeadacheNervous system disorders | 3/149 | 9/151 | 4/150 |
| Covid-19Infections and infestations | 8/149 | 8/151 | 7/150 |
Full analysis set (FAS) included all participants who were randomized in the study and included in the analyses.
| Age, Continuous(Years) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Mean | 49.2 ± 12.59 | 51.9 ± 12.91 | 50.6 ± 13.29 | 50.6 ± 12.95 |
| Age, Customized(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 132 | 126 | 127 | 385 |
| From 65 to 84 years | 18 | 25 | 23 | 66 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Female | 85 | 77 | 75 | 237 |
| Male | 65 | 74 | 75 | 214 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Hispanic or Latino | 22 | 18 | 18 | 58 |
| Not Hispanic or Latino | 127 | 128 | 132 | 387 |
| Unknown or Not Reported | 1 | 5 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 1 | 3 |
| Asian | 1 | 0 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 6 | 5 | 15 |
| White | 141 | 143 | 141 | 425 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 0 | 4 |
| Region of Enrollment(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| ARGENTINA | 7 | 9 | 8 | 24 |
| BULGARIA | 15 | 17 | 21 | 53 |
| CZECH REPUBLIC | 10 | 10 | 7 | 27 |
| HUNGARY | 8 | 7 | 9 | 24 |
| ISRAEL | 3 | 5 | 2 | 10 |
| MALAYSIA | 1 | 0 | 2 | 3 |
| POLAND | 39 | 42 | 38 | 119 |
| RUSSIAN FEDERATION | 10 | 13 | 5 | 28 |
| SPAIN | 2 | 1 | 4 | 7 |
| TURKEY | 5 | 4 | 4 | 13 |
| UKRAINE | 18 | 14 | 18 | 50 |
| UNITED STATES | 32 | 29 | 32 | 93 |
Showing the first 100 of 169 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2021 to primary completion in Oct 2024, 37 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 37 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →